Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.28 +1.3%	$1.19	$0.64 ▼ $2.92	$50.83M	-0.73	360,409 shs	12,061 shs
CGTX Cognition Therapeutics	$1.66 +36.1%	$0.57	$0.22 ▼ $1.81	$89.64M	1	6.66 million shs	32.25 million shs
CYCC Cyclacel Pharmaceuticals	$8.89 -0.1%	$7.49	$3.08 ▼ $597.60	$14.10M	0.08	1.86 million shs	90,286 shs
LTRN Lantern Pharma	$4.57 -4.0%	$3.80	$2.55 ▼ $6.12	$51.33M	1.6	390,794 shs	159,863 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	+3.73%	-12.01%	+25.09%	+35.16%	-4.07%
CGTX Cognition Therapeutics	+36.07%	+145.20%	+192.25%	+410.46%	+169.61%
CYCC Cyclacel Pharmaceuticals	-0.11%	-0.89%	-27.90%	-70.37%	-97.45%
LTRN Lantern Pharma	-3.99%	-8.42%	+21.54%	+37.65%	+15.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	2.4284 of 5 stars	3.5	3.0	0.9	0.8	1.3
CGTX Cognition Therapeutics	3.4595 of 5 stars	3.6	4.0	3.8	1.7	0.6
CYCC Cyclacel Pharmaceuticals	1.6676 of 5 stars	0.0	4.0	4.0	2.5	0.0
LTRN Lantern Pharma	2.7084 of 5 stars	3.5	3.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	135.13% Upside
CGTX Cognition Therapeutics	3.25	Buy	$2.83	70.68% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
LTRN Lantern Pharma	3.00	Buy	$25.00	447.05% Upside

Current Analyst Ratings Breakdown

Latest CYCC, CGTX, BRNS, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.44	N/A	N/A	$2.54 per share	0.50
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
CYCC Cyclacel Pharmaceuticals	$40K	351.16	N/A	N/A	($58.87) per share	-0.15
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	N/A
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	N/A
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-3,648.09%	-145.49%	N/A
LTRN Lantern Pharma	-$20.78M	-$1.84	N/A	N/A	N/A	N/A	-89.44%	-75.03%	N/A

Latest CYCC, CGTX, BRNS, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/15/2025	Q1 2025	LTRN Lantern Pharma	-$0.49	-$0.42	+$0.07	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
CGTX Cognition Therapeutics	N/A	1.54	1.54
CYCC Cyclacel Pharmaceuticals	N/A	5.60	5.60
LTRN Lantern Pharma	N/A	4.86	4.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
CGTX Cognition Therapeutics	43.35%
CYCC Cyclacel Pharmaceuticals	23.58%
LTRN Lantern Pharma	28.62%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
CGTX Cognition Therapeutics	14.40%
CYCC Cyclacel Pharmaceuticals	51.20%
LTRN Lantern Pharma	7.31%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	36.02 million	N/A
CGTX Cognition Therapeutics	20	73.47 million	62.89 million	Not Optionable
CYCC Cyclacel Pharmaceuticals	14	1.58 million	773,000	Optionable
LTRN Lantern Pharma	20	10.78 million	10.00 million	Optionable

CYCC, CGTX, BRNS, and LTRN Headlines

Recent News About These Companies

Lantern Pharma Narrows Loss in Q2

August 14 at 6:59 AM | aol.comA

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

August 13 at 5:04 PM | businesswire.com

Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy

August 7, 2025 | theglobeandmail.com

Lantern Pharma (LTRN) Projected to Post Quarterly Earnings on Thursday

August 7, 2025 | americanbankingnews.com

Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Grows By 109.5%

August 6, 2025 | marketbeat.com

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

August 4, 2025 | businesswire.com

Lantern Pharma (LTRN) Gets a Buy from Lake Street

August 4, 2025 | theglobeandmail.com

Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan

July 31, 2025 | theglobeandmail.com

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

July 31, 2025 | businesswire.com

Lantern Pharma Appoints Dr. Schalop to Board

July 30, 2025 | msn.com

Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

July 28, 2025 | theglobeandmail.com

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

July 28, 2025 | businesswire.com

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

July 26, 2025 | miamiherald.comM

Lantern reports complete response in pretreated Lymphoma patient with LP-284

July 24, 2025 | msn.com

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

July 23, 2025 | businesswire.com

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

July 21, 2025 | businesswire.com

IBN Initiates Coverage of Lantern Pharma Inc.

July 16, 2025 | finance.yahoo.com

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

July 15, 2025 | theglobeandmail.com

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

July 15, 2025 | businesswire.com

NASDAQ:LTRN Financials | Lantern Pharma Inc - Investing.com

July 9, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCC, CGTX, BRNS, and LTRN Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.28 +0.02 (+1.26%)

Closing price 08/14/2025 03:50 PM Eastern

Extended Trading

$1.30 +0.02 (+1.50%)

As of 08/14/2025 04:10 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Cognition Therapeutics NASDAQ:CGTX

$1.66 +0.44 (+36.07%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.62 -0.04 (-2.41%)

As of 04:31 AM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.89 -0.01 (-0.11%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$9.32 +0.43 (+4.88%)

As of 04:31 AM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Lantern Pharma NASDAQ:LTRN

$4.57 -0.19 (-3.99%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.37 -0.20 (-4.35%)

As of 04:05 AM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time